Advertisement

Drug Investigation

, Volume 7, Issue 4, pp 215–220 | Cite as

Safety Aspects of Fish Oils

Experiences with an n-3 Concentrate of Re-Esterified Triglycerides (Pikasol®)
  • Erik Berg Schmidt
  • Jørn Munkhof Møller
  • Niels Svaneborg
  • Jørn Dyerberg
Short Communication

Keywords

Uric Acid Drug Invest Tocopherol Level Monocyte Chemotaxis Term Supplementation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Frohlich ED. Uric acid: a risk factor for coronary heart disease. Journal of the American Medical Association 270: 378–379, 1993PubMedCrossRefGoogle Scholar
  2. Kannel WB, Anderson K, Wilson PWF. White blood cell count and cardiovascular disease: insights from the Framingham study. Journal of the American Medical Association 267: 1253–1256, 1992PubMedCrossRefGoogle Scholar
  3. Kristensen SD, Schmidt EB, Dyerberg J. Dietary supplementation with n-3 polyunsaturated fatty acids and human platelet function: a review with particular emphasis on implications for cardiovascular disease. Journal of Internal Medicine 225 (Suppl. 1): 141–150, 1989Google Scholar
  4. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. New England Journal of Medicine 318: 549–557, 1988PubMedCrossRefGoogle Scholar
  5. Nordøy A. Is there a rational use for n-3 fatty acids (fish oils) in clinical medicine? Drugs 42: 331–342, 1991PubMedCrossRefGoogle Scholar
  6. Schmidt EB, Dyerberg J. Omega-3 fatty acids: current status in cardiovascular medicine. Drugs 7: 405–424, 1994CrossRefGoogle Scholar
  7. Schmidt EB, Ernst E, Vanning K, Pedersen JO, Dyerberg J. The effect of n-3 fatty acids on lipids and haemostasis in patients with type IIa and type IV hyperlipidaemia. Thrombosis and Haemostasis 62: 797–801, 1989aPubMedGoogle Scholar
  8. Schmidt EB, Lervang H-H, Varming K, Madsen P, Dyerberg J. Long term supplementation with n-3 fatty acids. I: effects on blood lipids, hemostasis and blood pressure. Scandinavian Journal of Clinical and Laboratory Investigation 52: 221–228, 1992PubMedCrossRefGoogle Scholar
  9. Schmidt EB, Nielsen LK, Pedersen JO, Kornerup HJ, Dyerberg J. The effect of n-3 polyunsaturated fatty acids on lipids, platelet function, coagulation, fibrinolysis and monocyte chemotaxis in patients with hypertension. Clinica Chimica Acta 189: 25–32, 1990aCrossRefGoogle Scholar
  10. Schmidt EB, Sørensen PJ, Pedersen JO, Jersild C, Ditzel J, et al. The effect of n-3 polyunsaturated fatty acids on lipids, haemostasis, neutrophil and monocyte chemotaxis in insulin-dependent diabetes mellitus. Journal of Internal Medicine 225 (Suppl 1): 201–206, 1989bGoogle Scholar
  11. Schmidt EB, Varming K, Ernst E, Madsen P, Dyerberg J. Dose-response studies on the effect of n-3 polyunsaturated fatty acids on lipids and haemostasis. Thrombosis and Haemostasis 63: 1–5, 1990bPubMedGoogle Scholar
  12. Siegel S, Castellan NJ. Nonparametric statistics for the behavioral sciences. McGraw-Hill, New York, 1988Google Scholar
  13. Simopoulos AR. Omega-3 fatty acids in health and disease and in growth and development. American Journal of Clinical Nutrition 54: 438–463, 1991PubMedGoogle Scholar
  14. Witzkum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. Journal of Clinical Investigation 88: 1785–1792, 1991CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Erik Berg Schmidt
    • 1
  • Jørn Munkhof Møller
    • 2
  • Niels Svaneborg
    • 3
  • Jørn Dyerberg
    • 4
  1. 1.Department of HaematologyAalborg HospitalAalborgDenmark
  2. 2.Department of CardiologyAalborg HospitalAalborgDenmark
  3. 3.Department of Clinical ChemistryAalborg HospitalAalborgDenmark
  4. 4.Medi-Lab A/SCopenhagenDenmark

Personalised recommendations